Meeting News
-
2024 IASLC Academy to Once Again Compete in Amazing Case Race
After a successful inaugural year in 2023, participants have once again crafted case summaries, and WCLC 2024 attendees will help choose the winning cases.
-
Get Moving and Win During the 2024 Wellness Challenge
Stay active during your time in San Diego by taking part in IASLC’S Wellness Challenge, Step It Up for Research.
-
Know Before You Go: What You Need to Know to Get to—and Navigate—San Diego
With the 2024 World Conference on Lung Cancer less than a month away, now is the time to make sure you know where you’re headed and how to get there.
-
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population.
-
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2
In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative.
-
Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases
Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA.
-
Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC
Presenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need.
-
CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date
When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer.
-
Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC
Dr. Natasha Leighl said the findings of PALOMA-3 show subcutaneous dosing offers other advantages, including reduced adverse events.
-
KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC
Dr. Tony Mok said the results of the phase III KRYSTAL-12 trial reinforce adagrasib as an effective second-line treatment option for this patient population.
View ILCN Archives
Provider Resources